Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Core Viewpoint - Shares of Praxis Precision Medicines have reached their highest intraday level since March 2022 [1] Company Summary - Praxis Precision Medicines has experienced a significant increase in share price, indicating positive market sentiment and potential investor interest [1]